AMP vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMP's deterministic health score is weak with a Piotroski F-Score of 4/9, indicating borderline financial stability. Despite strong profitability metrics like a 59.59% ROE and solid earnings growth (YoY +86.6%), the stock trades above its Graham defensive value of $235.33 at $496.60, reflecting rich valuation. Earnings volatility, declining recent estimate beats, and bearish insider activity offset strong cash flow efficiency and low leverage. Analysts concur with a 'hold' rating, aligning with technical bearishness and mixed fundamentals.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
AMP vs JPM: Head-to-Head Comparison
This page compares Ameriprise Financial, Inc. (AMP) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.